Financials + Growth

While capital and funding environments for biotech companies are gradually showing signs of improvement, LabCentral's community is grateful to persevere, steadfastly advancing science and expanding knowledge frontiers in 2023. As we navigate these challenges, LabCentral and its affiliated companies boldly strategize ways to address investment needs and attract skilled personnel. We remain thankful for the opportunity to make impactful capital contributions within the demanding biotech landscape, driving innovation and progress forward. The below metrics and initiatives highlight our unwavering commitment to catalyzing positive change in biotechnology.

Outside 700
2023 Funds By Type MA 03


LabCentral Companies Raised $1.7BN in Funds

2023 Venture Impact

LabCentral companies raised $765M in early-stage funding.

Of the total early-stage biopharma venture funding in the US
Of the early-stage biopharma venture funding in Massachusetts

2023 Life-Science Industry Snapshot

447+ New life-science jobs created in Massachusetts 7 Mergers & acquisitions involving resident/alumni companies
Lab Central Team2 Cropped

2023 Patient Impact

Clinical trials launched
Patients dosed/enrolled
Patents granted
Co Lab Facility Front Desk

LabCentral, Inc. played a pivotal role in planning and developing Bayer AG's new life-science incubator, Co.Lab Cambridge. Situated in Kendall Square, it aims to empower cutting-edge cell and gene therapies (CGT) entrepreneurs with unparalleled expertise and top-notch facilities. The 26,000 square-foot facility operated by LabCentral, Inc. stands at the heart of Cambridge's strategic innovation ecosystem, offering direct access to leading pharma companies, research institutions, and venture capital offices. Leveraging its success and experience, Bayer chose LabCentral as its strategic partner to steer the build-out and operation of the Bayer Co.Lab. With LabCentral's involvement, Co.Lab residents will tap into Bayer's global expertise and network, driving scientific breakthroughs while preserving their independence amidst plans for global expansion.


Senator Di Domenico Headshot

"I am thrilled to see this new life-science incubator coming to Cambridge and Bayer recognizing our community as the perfect place to harness cutting edge research and entrepreneurship. This investment will expand business opportunities, spur economic development, create more jobs for my district, and will emphasize Cambridge’s importance as an international life-science hub."

Massachusetts State Senator Sal DiDomenico